Related Experiment Video
Updated: Apr 7, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Bivalirudin in ST-segment-elevation myocardial infarction: for better or worse?
Thomas A Mavrakanas1, Yiannis S Chatzizisis
1General Internal Medicine Division, Geneva University Hospitals, Geneva, Switzerland.
Insights
For ST-segment-elevation myocardial infarction patients undergoing percutaneous coronary intervention (PCI), bivalirudin and heparin offer comparable outcomes. Bivalirudin reduces bleeding, while heparin may lower stent thrombosis risk, necessitating individualized treatment selection.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Parenteral anticoagulants like bivalirudin and heparin are crucial for percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI).
- Both agents have demonstrated comparable hard clinical outcomes in STEMI patients undergoing PCI.
Purpose of the Study:
- To compare the safety and efficacy of bivalirudin versus heparin in STEMI patients undergoing PCI.
- To guide individualized selection of anticoagulation based on patient-specific risks.
Main Methods:
- Review of clinical outcomes comparing bivalirudin and heparin in STEMI patients undergoing PCI.
- Analysis of bleeding events and acute stent thrombosis rates associated with each anticoagulant.
Main Results:
- Bivalirudin use is associated with fewer bleeding events compared to heparin.
- Heparin use may be linked to a lower incidence of acute stent thrombosis compared to bivalirudin.
- Individualized anticoagulation selection is recommended based on patient's ischemic and bleeding risk profiles.
Conclusions:
- Bivalirudin may be preferred in STEMI patients with a higher bleeding risk.
- Heparin may be preferable in complex PCI cases with an elevated risk of stent thrombosis.
- Further research is needed to define optimal anticoagulation strategies in the evolving landscape of STEMI treatment.
Abstract:
Bivalirudin and heparin are the major available parenteral anticoagulants for percutaneous coronary intervention (PCI) in ST-segment-elevation myocardial infarction. Even though hard clinical outcomes are comparable with both drugs, bivalirudin appears to be safer (less bleeding events) at the expense of lower short-term efficacy (more acute stent thrombosis events). The selection of anticoagulation during PCI in ST-segment-elevation myocardial infarction should be individualized, taking into account the patient's ischemic and bleeding risk. In patients with increased bleeding risk, bivalirudin might be preferable to heparin, whereas in complex PCI with increased risk for stent thrombosis, heparin is preferable. Further clinical studies are needed to elucidate the role of these drugs in PCI for ST-segment-elevation myocardial infarction in the era of radial approaches, new potent antiplatelet agents and the use of glycoprotein IIb/IIIa inhibitors.
More Related Videos
05:52Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
Published on: November 4, 2021
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:14Myocarditis III: Medical Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...